ReviewFrontiers in neuroscience2018
Representing Diversity in the Dish: Using Patient-Derived
Review in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Graphene nanoplatelets enhance neuronal differentiation of human bone marrow mesenchymal stem cells.Biological research · 2025Article
- Advances in currentFrontiers in bioengineering and biotechnology · 2023Review
- Transcriptional signatures in iPSC-derived neurons are reproducible across labs when differentiation protocols are closely matched.Stem cell research · 2021Article
- Review
- The Emergence of Model Systems to Investigate the Link Between Traumatic Brain Injury and Alzheimer's Disease.Frontiers in aging neuroscience · 2021Review
- Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies.Frontiers in genome editing · 2021Review
- Human Autopsy-Derived Scalp Fibroblast Biobanking for Age-Related Neurodegenerative Disease Research.Cells · 2020Article
- Human pluripotent stem cell-derived models and drug screening in CNS precision medicine.Annals of the New York Academy of Sciences · 2020Review
- Mechanical regulation of oligodendrocyte biology.Neuroscience letters · 2020Review
- Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility.Disease models & mechanisms · 2020Review
- Progress of Induced Pluripotent Stem Cell Technologies to Understand Genetic Epilepsy.International journal of molecular sciences · 2020Review
- From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis.Frontiers in neuroscience · 2020Review
- Next-generation disease modeling with direct conversion: a new path to old neurons.FEBS letters · 2019Review
- Sonic Hedgehog Signaling Is Required for Cyp26 Expression during Embryonic Development.International journal of molecular sciences · 2019Article
- Induced pluripotent stem cells for neural drug discovery.Drug discovery today · 2019Review
- Reduced variability of neural progenitor cells and improved purity of neuronal cultures using magnetic activated cell sorting.PloS one · 2019Article
- Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells.Neurochemical research · 2018Review
- Designing well-defined photopolymerized synthetic matrices for three-dimensional culture and differentiation of induced pluripotent stem cells.Biomaterials science · 2018Article
- 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.Molecular neurodegeneration · 2018Review
- Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Neurological diseases, including dementias such as Alzheimer's disease (AD) and fronto-temporal dementia (FTD) and degenerative motor neuron diseases such as amyotrophic lateral sclerosis (ALS), are responsible for an increasing fraction of worldwide fatalities. Researching these heterogeneous diseases requires models that endogenously express the full array of genetic and epigenetic factors which may influence disease development in both familial and sporadic patients. Here, we discuss the two primary methods of developing patient-derived neurons and glia to model neurodegenerative disease: reprogramming somatic cells into induced pluripotent stem cells (iPSCs), which are differentiated into neurons or glial cells, or directly converting (DC) somatic cells into neurons (iNeurons) or glial cells. Distinct differentiation techniques for both models result in a variety of neuronal and glial cell types, which have been successful in displaying unique hallmarks of a variety of neurological diseases. Yield, length of differentiation, ease of genetic manipulation, expression of cell-specific markers, and recapitulation of disease pathogenesis are presented as determining factors in how these methods may be used separately or together to ascertain mechanisms of disease and identify therapeutics for distinct patient populations or for specific individuals in personalized medicine projects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.